More than 40,000 previously unknown gut microbes in African populations could completely change how medicines work for millions of people, according to scientists.
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod – Pharmaceutical Technology
Fasenra generated $1.55bn last year, according to AstraZeneca’s financials. Image credit: Alexanderstock23 / Shutterstock. AstraZeneca‘s Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in